Your browser doesn't support javascript.
loading
The effect of chitosan nanospheres on the immunogenicity of Toxoplasma lysate vaccine in mice.
El Temsahy, Mona M; El Kerdany, Eman D H; Eissa, Maha M; Shalaby, Thanaa I; Talaat, Iman M; Mogahed, Nermine M F H.
Afiliação
  • El Temsahy MM; Department of Medical Parasitology, Faculty of Medicine, University of Alexandria, Alexandria, Egypt.
  • El Kerdany ED; Department of Medical Parasitology, Faculty of Medicine, University of Alexandria, Alexandria, Egypt.
  • Eissa MM; Department of Medical Parasitology, Faculty of Medicine, University of Alexandria, Alexandria, Egypt.
  • Shalaby TI; Department of Biophysics and Biomedics, Medical Research Institute, University of Alexandria, Alexandria, Egypt.
  • Talaat IM; Department of Pathology, Faculty of Medicine, University of Alexandria, Alexandria, Egypt.
  • Mogahed NM; Department of Medical Parasitology, Faculty of Medicine, University of Alexandria, Alexandria, Egypt.
J Parasit Dis ; 40(3): 611-26, 2016 Sep.
Article em En | MEDLINE | ID: mdl-27605755
ABSTRACT
Toxoplasmosis, a zoonotic parasitic disease, is a huge challenge for which there is no effective vaccine up till now. In this study, chitosan nanospheres encapsulated with Toxoplasma lysate vaccine was evaluated for its ability to protect mice against both acute and chronic toxoplasmosis models of infection. Results showed that chitosan nanospheres were equally effective to Freund's incomplete adjuvant (FIA) in enhancing the efficacy of Toxoplasma lysate vaccine. The effectiveness was demonstrated by the delayed death of vaccinated mice following challenge either with virulent RH or avirulent Me49 strains, the significant decrease in parasite density in different organs, significant increase in the humoral and cellular immune response (IgG and IFN γ) with a marked reduction of pathological changes in the different organs. However chitosan nanospheres were superior to FIA due to their cost effective preparation and much less necrotic changes induced in the studied organs. The success of chitosan polymer as an alternative to commonly used adjuvants paves the way for the use of other newly developed polymers to be used in the field of vaccine development.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2016 Tipo de documento: Article